Clinical Trial Update: First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating first-line lenvatinib in patients with Child-Pugh B liver function and advanced hepatocellular carcinoma unsuitable for c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING